Protein markers of ovarian cancer and its subtypes: insights from proteome-wide Mendelian randomisation analysis
Our study suggests FSHB and 11 additional plasma proteins as of potential interest in OC (or subtypes) prognosis, mostly representing potentially druggable targets.
Authors
- Martin K. Oehler (ORCID: https://orcid.org/0000-0002-2651-5913)
- Elina Hyppönen (ORCID: https://orcid.org/0000-0003-3670-9399)
- Iqbal Madakkatel (ORCID: https://orcid.org/0000-0003-2339-5917)
- Amanda L. Lumsden (ORCID: https://orcid.org/0000-0002-0214-6498)
- Sang Lee (ORCID: https://orcid.org/0000-0001-9701-2718)
- David Stacey (ORCID: https://orcid.org/0000-0002-9392-9235)
- Johanna Mäenpää (ORCID: https://orcid.org/0000-0003-0486-6912)
- Anwar Mulugeta (ORCID: https://orcid.org/0000-0002-8018-3454)
Institutions
- Royal Adelaide Hospital (AU)
- Tampere University (FI)
- University of South Australia (AU)
- Tampere University Hospital (FI)
- Tampere University (FI)
- South Australian Health and Medical Research Institute (AU)
- Addis Ababa University (ET)
- The University of Adelaide (AU)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2025-08-28
- DOI
- https://doi.org/10.1038/s41416-025-03143-w
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00